Raj Kalkeri

Novavax (United States) — United States

Medicine · Health Sciences

16h-index921citations73works3.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

SARS-CoV-2 and COVID-19 Research(44), Animal Virus Infections Studies(14), SARS-CoV-2 detection and testing(11), COVID-19 Clinical Research Studies(10), Mosquito-borne diseases and control(8)

Publications73 total

Abstract C066: <i>Matrix-M adjuvant – A promising adjuvant for preventative and therapeutic cancer vaccines development</i>
Cancer Immunology Research·2026
Immunogenicity and safety of a recombinant spike protein COVID vaccine in patients with inflammatory bowel disease and transplant recipient
Vaccine·2026Open Access
P-1655. Anti-Spike IgG4 and Fc Effector Responses: The Impact of SARS-CoV-2 Vaccine Platform–Specific Priming and Immune Imprinting
Open Forum Infectious Diseases·2026Open Access
Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trial
Vaccine·2025Open Access
Detection of Anti‐SARS‐CoV‐2 Mucosal Immunoglobulin A in Clinical Saliva Samples After a Dose of Novavax COVID‐19 Vaccine
Journal of Medical Virology·2025Open Access
Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trial
2025Open Access
Anti-spike IgG4 and Fc effector responses: The impact of SARS-CoV-2 vaccine platform–specific priming and immune imprinting
Journal of Infection·2025· 4 citedOpen Access
Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: A phase 3, randomized, placebo-controlled trial (PREVENT-19)
Vaccine·2025· 1 citedOpen Access
Phase 2/3 open-label study on NVX-CoV-2601 (XBB.1.5) vaccine in previously COVID-19 mRNA vaccinated and vaccine-naive participants: a 6-month follow-up
2025Open Access
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: Primary day-28 analysis of a phase 2/3 open-label study
Vaccine·2025· 2 citedOpen Access
Anti-Spike IgG4 and Fc Effector Responses: The Impact of SARS-CoV-2 Vaccine Platform–Specific Priming and Immune Imprinting
2025Open Access
Immunogenicity of adjuvanted recombinant SARS-CoV-2 spike protein vaccine after earlier mRNA vaccine doses
Journal of Allergy and Clinical Immunology·2025Open Access
P-1972. SARS-CoV-2 Vaccine–Induced IgG4 Response Negatively Correlates with Neutralizing Antibodies and Fc Effector Functions
Open Forum Infectious Diseases·2025Open Access
Safety and immunogenicity of Omicron protein vaccines in mRNA-vaccinated adolescents: A phase 3, randomised trial
Journal of Infection·2025· 3 citedOpen Access
Detection of anti–SARS-CoV-2 mucosal IgA in clinical saliva samples after a dose of Novavax COVID-19 vaccine
2025· 3 citedOpen Access
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study
The Lancet Infectious Diseases·2025· 8 cited
A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine
Microorganisms·2024· 1 citedOpen Access
Safety and immunogenicity of four sequential doses of NVX-CoV2373 in adults and adolescents: a phase 3, randomized, placebo-controlled trial (PREVENT-19)
2024Open Access
Adjuvant Recombinant SARS-CoV-2 Spike Protein Vaccine Immunogenicity After Prior mRNA Vaccine Doses
2024Open Access
Safety and Immunogenicity of Omicron Protein Vaccines in mRNA-Vaccinated Adolescents: A Phase 3, Randomised Trial
2024· 1 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Joyce S. Plested(26), Mingzhu Zhu(24), Shane Cloney-Clark(17), Zhaohui Cai(16), Raburn M. Mallory(14), Fusataka Koide(10), Louis Fries(9), Nita Patel(8), Roger G. Ptak(8), Gordon Chau(8), Anthony M. Marchese(7), Gale Smith(7), Rongman Cai(7), Shane Cloney‐Clark(7), Scott J. Goebel(6), Gregory M. Glenn(6), Chijioke Bennett(6), Katherine Clegg Smith(6), Beth A. Snyder(5), Kevin Walters(5)